Sonn-Segev, Adar
Belacic, Katarina http://orcid.org/0000-0002-4024-5497
Bodrug, Tatyana
Young, Gavin
VanderLinden, Ryan T.
Schulman, Brenda A. http://orcid.org/0000-0002-3083-1126
Schimpf, Johannes
Friedrich, Thorsten http://orcid.org/0000-0002-0813-7883
Dip, Phat Vinh http://orcid.org/0000-0002-1535-9644
Schwartz, Thomas U. http://orcid.org/0000-0001-8012-1512
Bauer, Benedikt
Peters, Jan-Michael
Struwe, Weston B.
Benesch, Justin L. P. http://orcid.org/0000-0002-1507-3742
Brown, Nicholas G. http://orcid.org/0000-0002-6141-0164
Haselbach, David http://orcid.org/0000-0002-5276-5633
Kukura, Philipp http://orcid.org/0000-0003-0136-7704
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (PHOTOMASS 819593, 693949)
Foundation for the National Institutes of Health (T32GM00857, R37GM065930, P30CA021765, R01GM77537, R35GM128855, P30AI050410)
National Science Foundation (DGE-1650116)
Howard Hughes Medical Institute
Deutsche Forschungsgemeinschaft (278002225/RTG 2202, FR 1140/11-2)
European Molecular Biology Organization
Human Frontier Science Program (RGP0057/2018)
Boehringer Ingelheim
Österreichische Forschungsförderungsgesellschaft (FFG-852936)
UNC | UNC-Chapel Hill | Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Article History
Received: 20 January 2020
Accepted: 12 March 2020
First Online: 14 April 2020
Competing interests
: P.K. is a founder, director and shareholder in Refeyn Ltd. W.B.S. is a consultant and shareholder in Refeyn Ltd. G.Y. and J.L.P.B. are founders, consultants and shareholders in Refeyn Ltd. All other authors declare no competing interest.